Altogether, these results suggest that high EphA2 expression is associated with longer survival of HER2-negative breast cancers with low RNF5 expression, in which leads to that EphA2 acts as a tumor suppressor and improved prognosis under RNF5 inhibition in ER-positive HER2-negative breast cancers. This evidence concerns the gene ERBB2 and breast cancer.